Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks

about

Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks

Item

http://www.wikidata.org/entity/Q36533132

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Repeated oral dose tolerance i ...... nd oclacitinib for three weeks

@ast

Repeated oral dose tolerance i ...... nd oclacitinib for three weeks

@en

type

Item

label

Repeated oral dose tolerance i ...... nd oclacitinib for three weeks

@ast

Repeated oral dose tolerance i ...... nd oclacitinib for three weeks

@en

prefLabel

Repeated oral dose tolerance i ...... nd oclacitinib for three weeks

@ast

Repeated oral dose tolerance i ...... nd oclacitinib for three weeks

@en

P1476

Repeated oral dose tolerance i ...... nd oclacitinib for three weeks

@en

P2093

Alessandro Panteri

http://www.w3.org/2001/XMLSchema#string

Christine Prost

http://www.w3.org/2001/XMLSchema#string

Günther Strehlau

http://www.w3.org/2001/XMLSchema#string

Kelly Doucette

http://www.w3.org/2001/XMLSchema#string

Rainer Helbig

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclosporin A: a new drug in the field of canine dermatology

Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.

Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.

A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.

Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis

A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA).

A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs.

The use of ciclosporin A in veterinary dermatology.

P304

22-e7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VDE.12278

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26660461

http://www.w3.org/2001/XMLSchema#string

P932

4737300

http://www.w3.org/2001/XMLSchema#string